Company intelligence / Profile preview

PolyTherics

London, England, United Kingdom
Ownership
Private
Development stage
Other
01

Overview

PolyTherics developed proprietary polymer-based technologies for site-specific conjugation and PEGylation of therapeutic proteins, enabling improved pharmacokinetics/stability. Their platforms have been licensed by major pharma partners for use in developing next-generation biologic drugs including ADCs. After merging with Antitope in July 2013, they became part of what would become Abzena—a leading global provider of integrated solutions for biopharmaceutical development. Products using their technology were advancing toward clinical trials at time of merger but no independent clinical results are attributed solely to "PolyTherics."[1][3][4]

Therapeutic areas
OncologyOther
Modalities
Monoclonal antibodiesAntibody-drug conjugates (ADCs)VaccinesOligonucleotides[2]PEGylated proteins/peptides[1][4]
Industry
Drug Discovery Services
02

Partnerships

Top five pharmaceutical companies (undisclosed)Spirogen Limited collaboration on novel ADCsCritical Pharmaceuticals collaboration on sustained release systemsnumerous international biotech/pharma clients including many top industry players.[1][4]

Beyond the preview

Go deeper on PolyTherics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolyTherics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call